Abu Dhabi: Borouge, a prominent petrochemicals company, signed an agreement with Mubadala Bio to boost local production of medical-grade materials.
The partnership was sealed during the ongoing Make it in the Emirates forum and is part of the country's broader strategy to enhance its healthcare and life sciences sectors by reducing dependency on imported medical products and supporting national industrial resilience.
The agreement directly contributes to the UAE’s Operation 300 Billion strategy and aligns with the Make it in the Emirates industrial policy, aimed at expanding local manufacturing capabilities.
Under this collaboration, Borouge will provide Mubadala Bio with specialised polyolefins tailored for medical use.
The initial focus will be on Bormed™ RG868MO, the country’s first domestically produced medical-grade polyolefin. Already manufactured at Borouge’s Al Ruwais facility, this material meets stringent sterilisation and mechanical requirements and is suitable for use in syringes, inhalers, and pharmaceutical packaging.
Mubadala Bio, officially launched this week, consolidates pharmaceutical manufacturing and logistics under one umbrella, enhancing the UAE’s role in global healthcare supply chains.
The platform is designed to serve over 100 countries through 10 facilities worldwide, with six located in the UAE.
Its annual production capacity includes 2.5 billion tablets and 120 million injectables, positioning it as a major player in improving local drug availability and driving down the cost of essential treatments.
Executives from both companies highlighted that the partnership is a testament to their shared commitment to innovation, sustainability, and national healthcare self-sufficiency.
By supporting the localisation of advanced medical materials, the initiative not only strengthens the UAE’s domestic capabilities but also reinforces its ambition to become a global hub for medical manufacturing and life sciences innovation.
